NDAORALLIQUID
Approved
Feb 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAVICTI (glycerol phenylbutyrate) is an oral liquid formulation used to treat urea cycle disorders (UCDs), rare genetic metabolic conditions that impair ammonia detoxification. It works as a nitrogen scavenger, providing an alternative pathway for waste nitrogen excretion and reducing hyperammonemia.
$73MPart D
PeakStable
5.7 years to LOEEstablished peak-stage product with modest but stable Medicare utilization; commercial team likely focused on patient support and therapy optimization rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
Started Feb 2018
16 enrolled
Urea Cycle Disorder
A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders
Started Dec 2014
27 enrolled
Urea Cycle Disorder
Career Relevance
RAVICTI careers are concentrated in rare disease commercial execution, patient support infrastructure, and payer management rather than high-volume promotion or clinical development. Roles emphasize relationship-building with specialized metabolic disease physicians and genetic counselors in ultra-rare disease networks.
Worked on RAVICTI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.